In a recent issue of JAMA, Lewis et al. present long-term data on the likelihood of a link between pioglitazone and the risk of bladder cancer and ten other cancers. Their findings contradict previous concerns regarding the safety of pioglitazone, and add to the controversy surrounding interpretation of rare adverse events associated with prescription drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fontanarosa, P. B., Bauchner, H. & Golub, R. M. Evaluating research on the safety of medical therapies: the responsibility of journals to the health of the public. JAMA 314, 235–236 (2015).
Sharfstein, J. M. & Kesselheim, A. S. The safety of prescription drugs. JAMA 314, 233–234 (2015).
Lewis, J. D. et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons With diabetes. JAMA 314, 265–277 (2015).
Turner, R. M. et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 78, 258–273 (2014).
Loke, Y. K., Singh, S. & Furberg, C. D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180, 32–39 (2009).
Singh, S., Loke, Y. K. & Furberg, C. D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30, 2148–2153 (2007).
Food and Drug Administration. FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines [online], (2011).
Lewis, J. D. et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34, 916–922 (2011).
Levin, D. et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58, 493–504 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Loke, Y., Mattishent, K. Pioglitazone—when is a prescription drug safe?. Nat Rev Urol 12, 655–656 (2015). https://doi.org/10.1038/nrurol.2015.237
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.237
This article is cited by
-
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Nature Reviews Clinical Oncology (2017)
